MONARCH-3 trial
Feb 15, 2023
KEY POINTS
In the second interim analysis of the phase III MONARCH-3 study, that was presented by Dr Matthew Goetz adding #Abemaciclib to first line endocrine therapy resulted in numerical improvement of the overall survival with HR of 0.754 (p=0.0301). This didn’t reach the statistical significance boundary of this interim analysis. The final results are awaited next year. Of note, in the 2 phase III trials with similar design, #ribociclib significantly improved OS in the MONALEESA-2 study and #palbociclib failed to improve OS in the PALOMA-2 study.
In the second interim analysis of the phase III MONARCH-3 study, that was presented by Dr Matthew Goetz adding #Abemaciclib to first line endocrine therapy resulted in numerical improvement of the overall survival with HR of 0.754 (p=0.0301). This didn’t reach the statistical significance boundary of this interim analysis. The final results are awaited next year. Of note, in the 2 phase III trials with similar design, #ribociclib significantly improved OS in the MONALEESA-2 study and #palbociclib failed to improve OS in the PALOMA-2 study.
.png)